Literature DB >> 18203843

Pleiotropic effects of the CB2 cannabinoid receptor activation on human monocyte migration: implications for atherosclerosis and inflammatory diseases.

Pál Pacher, Zoltán Ungvári.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18203843      PMCID： PMC2267750          DOI： 10.1152/ajpheart.00020.2008

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN： 0363-6135            Impact factor:   4.733


× No keyword cloud information.
  28 in total

Review 1.  The cannabinoid system and immune modulation.

Authors:  Thomas W Klein; Cathy Newton; Kellie Larsen; Lily Lu; Izabella Perkins; Liang Nong; Herman Friedman
Journal:  J Leukoc Biol       Date:  2003-07-01       Impact factor: 4.962

Review 2.  The endocannabinoid system and its therapeutic exploitation.

Authors:  Vincenzo Di Marzo; Maurizio Bifulco; Luciano De Petrocellis
Journal:  Nat Rev Drug Discov       Date:  2004-09       Impact factor: 84.694

Review 3.  Chemoattractant receptor cross-desensitization.

Authors:  H Ali; R M Richardson; B Haribabu; R Snyderman
Journal:  J Biol Chem       Date:  1999-03-05       Impact factor: 5.157

Review 4.  CB2 receptor-mediated migration of immune cells: it can go either way.

Authors:  A M Miller; N Stella
Journal:  Br J Pharmacol       Date:  2007-11-05       Impact factor: 8.739

Review 5.  CB2 receptors as new therapeutic targets for liver diseases.

Authors:  S Lotersztajn; F Teixeira-Clerc; B Julien; V Deveaux; Y Ichigotani; S Manin; J Tran-Van-Nhieu; M Karsak; A Zimmer; A Mallat
Journal:  Br J Pharmacol       Date:  2007-10-22       Impact factor: 8.739

6.  Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice.

Authors:  Sabine Steffens; Niels R Veillard; Claire Arnaud; Graziano Pelli; Fabienne Burger; Christian Staub; Meliha Karsak; Andreas Zimmer; Jean-Louis Frossard; François Mach
Journal:  Nature       Date:  2005-04-07       Impact factor: 49.962

Review 7.  Endocannabinoids.

Authors:  R Mechoulam; E Fride; V Di Marzo
Journal:  Eur J Pharmacol       Date:  1998-10-16       Impact factor: 4.432

8.  CB2 cannabinoid receptor agonists attenuate TNF-alpha-induced human vascular smooth muscle cell proliferation and migration.

Authors:  M Rajesh; P Mukhopadhyay; G Haskó; J W Huffman; K Mackie; P Pacher
Journal:  Br J Pharmacol       Date:  2007-11-12       Impact factor: 8.739

9.  Cannabinoid CB2 receptor activation reduces mouse myocardial ischemia-reperfusion injury: involvement of cytokine/chemokines and PMN.

Authors:  Clara Di Filippo; Francesco Rossi; Settimio Rossi; Michele D'Amico
Journal:  J Leukoc Biol       Date:  2003-12-04       Impact factor: 4.962

10.  CB2 cannabinoid receptor agonist JWH-015 modulates human monocyte migration through defined intracellular signaling pathways.

Authors:  Fabrizio Montecucco; Fabienne Burger; François Mach; Sabine Steffens
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-01-04       Impact factor: 4.733
View more
  5 in total

1.  Anti-inflammatory cannabinoids in diet: Towards a better understanding of CB(2) receptor action?

Authors:  Jürg Gertsch
Journal:  Commun Integr Biol       Date:  2008

Review 2.  Is lipid signaling through cannabinoid 2 receptors part of a protective system?

Authors:  P Pacher; R Mechoulam
Journal:  Prog Lipid Res       Date:  2011-02-02       Impact factor: 16.195

3.  Cannabinoid receptor type 2 (CB2) deficiency alters atherosclerotic lesion formation in hyperlipidemic Ldlr-null mice.

Authors:  Courtney D Netherland; Theresa G Pickle; Alicia Bales; Douglas P Thewke
Journal:  Atherosclerosis       Date:  2010-08-19       Impact factor: 5.162

Review 4.  Modulating the endocannabinoid system in human health and disease--successes and failures.

Authors:  Pál Pacher; George Kunos
Journal:  FEBS J       Date:  2013-04-22       Impact factor: 5.542

Review 5.  Endocannabinoids as Guardians of Metastasis.

Authors:  Irmgard Tegeder
Journal:  Int J Mol Sci       Date:  2016-02-10       Impact factor: 5.923
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.